ArticleClinical ophthalmology (Auckland, N.Z.)2025
Caregiver Burden Among Patients Receiving Anti-VEGF Intravitreal Injections for AMD and DR: A Cross-Sectional Study in Guangzhou.
Article in Clinical ophthalmology (Auckland, N.Z.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Article
- Adverse Events Reported with Standard-Dose and High-Dose Aflibercept: A FAERS Pharmacovigilance Study.Vision (Basel, Switzerland) · 2026Article
- Fellow-eye effect of intravitreal aflibercept 8mg in a patient with bilateral refractory nAMD: a case report and literature review.BMC ophthalmology · 2026Review
- Beyond Vision: Prospective Real-World Evaluation of Quality-of-Life and Caregiver Burden in Diabetic Macular Edema Treated with Fluocinolone Acetonide (IluvienOphthalmology and therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To evaluate the caregiver burden and its associated factors among patients receiving anti-VEGF intravitreal injections for age-related macular degeneration (AMD) and diabetic retinopathy (DR) in a tertiary hospital in Guangzhou, China. Methods: This cross-sectional study recruited 88 patients who received intravitreal anti-VEGF injections and their primary caregivers. Patients completed the Activities of Daily Living (ADL) scale, while caregivers completed the Zarit Burden Interview (ZBI) and the Connor-Davidson Resilience Scale (CD-RISC). One-way ANOVA and Pearson correlation analysis were conducted to assess the associations between patient function, caregiver burden, and related sociodemographic factors. Results: The mean ADL score of patients was 18.99 ± 8.34, while the mean caregiver burden score was 18.22 ± 18.04. A significant positive correlation was found between the patient's ADL score and caregiver burden (r = 0.405, p < 0.01). Caregivers who were employed part-time or not cohabiting with patients reported significantly higher burden scores (p = 0.034 and p = 0.03, respectively). Additionally, the caregiver burden among DR patients was higher than among AMD patients (p = 0.026). Conclusion: Significant caregiver burden exists among those assisting patients receiving intravitreal injections, especially for DR patients and those with reduced ADL function. Caregiver availability and living arrangements should be considered in the design of follow-up schedules to improve treatment adherence and outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.